Liu WY, Chien CW, Tung TH. Healthcare practice strategies for integrating personalized medicine: Management of COVID-19. World J Clin Cases 2021; 9(29): 8647-8657 [PMID: 34734043 DOI: 10.12998/wjcc.v9.i29.8647]
Corresponding Author of This Article
Tao-Hsin Tung, PhD, Director, Evidence-based Medicine Center, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No. 150 Ximen Road, Linhai City, Linhai 317000, Zhejiang Province, China. ch2876@gmail.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 16, 2021; 9(29): 8647-8657 Published online Oct 16, 2021. doi: 10.12998/wjcc.v9.i29.8647
Healthcare practice strategies for integrating personalized medicine: Management of COVID-19
Wen-Yi Liu, Ching-Wen Chien, Tao-Hsin Tung
Wen-Yi Liu, Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, MD 21205, United States; Shanghai Bluecross Medical Science Institute, Shanghai 201100, Shanghai Province, China
Wen-Yi Liu, Ching-Wen Chien, Institute for Hospital Management, Tsing Hua University, Shenzhen Campus, Shenzhen 518055, Guangdong Province, China
Tao-Hsin Tung, Evidence-based Medicine Center, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai 317000, Zhejiang Province, China
Author contributions: Liu WY and Tung TH had full assessment for all of the data in the study and take responsibility for the integrity and accuracy of the data; Chien CW contributed to data interpretation and drafting the manuscript; all authors provided a critical review and approved the final manuscript.
Conflict-of-interest statement: The authors have no proprietary interest in any aspect of this review.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tao-Hsin Tung, PhD, Director, Evidence-based Medicine Center, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No. 150 Ximen Road, Linhai City, Linhai 317000, Zhejiang Province, China. ch2876@gmail.com
Received: February 17, 2021 Peer-review started: February 17, 2021 First decision: March 11, 2021 Revised: March 22, 2021 Accepted: August 18, 2021 Article in press: August 18, 2021 Published online: October 16, 2021 Processing time: 240 Days and 8.3 Hours
Abstract
Personalized medicine is the tailor-made clinical treatment to the individual characteristics of each patient. It may be considered an extension of traditional approaches to knowing and treating diseases. Personalized medicine has the potential to change the way of identification and management of health problems. Coronavirus disease 2019 (COVID-19) is an infectious disease that primarily affects the patients’ lungs. The first case of pneumonia of unknown cause was reported in Wuhan, China on December 31, 2019. As thus, we are quickly approaching the era of personalized medicine. This review discusses the practices currently used in the management of COVID-19 and how they relate to personalized medicine.
Core Tip: For patients with coronavirus disease 2019 (COVID-19), providing the most effective treatment is a task of paramount importance in personalized medicine. The pandemic of COVID-19 is the opportunity and challenge to change toward a more personalized approach taking patients’ needs into consideration. Personalized medicine related research is ideally suited to dealing with infectious diseases; however, there has been relatively little research in this area.
